Chemotherapy with or without low-dose interleukin-2 in advanced non-small cell lung cancer: Results from a phase III randomized multicentric trial

International Journal of Oncology

Volumn 39, Issue 4, 2011, Pages 1011-1017

  Ridolfi, Laura ^a   Bertetto, Oscar ^b   Santo, Antonio ^c   Naglieri, Emanuele ^d   Lopez, Massimo ^e   Recchia, Francesco ^f   Lissoni, Paolo ^g   Galliano, Marco ^h   Testore, Franco ⁱ   Porta, Camillo ^j   Maglie, Monica ^a   Dall'Agata, Monia ^a   Fumagalli, Luca ^g   Ridolfi, Ruggero ^a  

^a DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

^b MOLINETTE HOSPITAL   (Italy)

^c BORGO TRENTO HOSPITAL   (Italy)

^d NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^e REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^f SS Filippo e Nicola Hospital   (Italy)

^g SAN GERARDO HOSPITAL   (Italy)

^h Department of Medical Oncology   (Italy)

ⁱ Department of Medical Oncology   (Italy)

^j FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

more..

Author keywords

Chemotherapy; Combination therapy; Low dose IL 2; NSCLC

Indexed keywords

CISPLATIN; GEMCITABINE; INTERLEUKIN 2;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; DIARRHEA; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; FEVER; GRANULOCYTOPENIA; HUMAN; IMMUNE DEFICIENCY; LEUKOPENIA; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; REGULATORY T LYMPHOCYTE; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERLEUKIN-2; LUNG NEOPLASMS; MAINTENANCE CHEMOTHERAPY; MALE; MEDICATION ADHERENCE; MIDDLE AGED; NEOPLASM STAGING;

EID: 79960858227     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.1099     Document Type: Article

References (55)

1. Karim-Kos H, De Vries E, Soerjomataram I, Lemmens V, Siesling S and Coebergh J: Recent trends of cancer in Europe: a combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s. Eur J Cancer 44: 1345-1389, 2008.
2. Verdecchia A, Francisci S, Brenner H, Gatta G, Micheli A, Mangone L and Kunkler I; EUROCARE-4 Working Group: Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data. Lancet Oncol 8: 784-796, 2007. (Pubitemid 47321601)
3. Schiller J, Harrington D, Belani C, et al: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346: 92-98, 2002. (Pubitemid 34438899)
4. Kelly K, Crowley J, Bunn PA Jr, et al: Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 19: 3210-3218, 2001. (Pubitemid 32591438)
5. Scagliotti G, De Marinis F, Rinaldi M, et al: Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 20: 4285-4291, 2002. (Pubitemid 35266288)
6. Le Chevalier T, Scagliotti G, Natale R, et al: Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes. Lung Cancer 47: 69-80, 2005. (Pubitemid 39643243)
7. Scagliotti G, Parikh P, von Pawel J, et al: Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26: 3543-3551, 2008.
8. Scagliotti G, Hanna N, Fossella F, et al: The differential efficacy of pemetrexed according to NSCLC histology: a review of two phase III studies. Oncologist 14: 253-263, 2009.
9. Douillard J, Laporte S, Fossella F, et al: Comparison of docetaxel- and vinca alkaloid-based chemotherapy in the first-line treatment of advanced non-small cell lung cancer: a meta-analysis of seven randomized clinical trials. J Thorac Oncol 2: 939-946, 2007. (Pubitemid 47511598)
10. Grossi F, Aita M, Defferrari C, et al: Impact of third-generation drugs on the activity of first-line chemotherapy in advanced non-small cell lung cancer: a meta-analytical approach. Oncologist 14: 497-510, 2009.
11. Ciuleanu T, Brodowicz T, Zielinski C, et al: Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 374: 1432-1440, 2009.
12. Fidias P, Dakhil S, Lyss A, et al: Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 27: 591-598, 2009.
13. Cappuzzo F, Ciuleanu T, Stelmakh L, et al: Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 11: 521-529, 2010.
14. Miller VA, O'Connor P, Soh C, Kabbinavar F, for the ATLAS Investigators: A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). Proc ASCO 27 (18S): abs. LBA80022009, 2009.
15. Lange J, Raubitschek A, Pockaj B, et al: A pilot study of the combination of interleukin-2-based immunotherapy and radiation therapy. J Immunother 12: 265-271, 1992.
16. Tester W, Kim K, Krigel R, et al: A randomized Phase II study of interleukin-2 with and without beta-interferon for patients with advanced non-small cell lung cancer: an Eastern Cooperative Oncology Group study (PZ586). Lung Cancer 25: 199-206, 1999. (Pubitemid 29421627)
17. Ardizzoni A, Bonavia M, Viale M, et al: Biologic and clinical effects of continuous infusion interleukin-2 in patients with non-small cell lung cancer. Cancer 73: 1353-1360, 1994. (Pubitemid 24072539)
18. Lissoni P, Barni S, Rovelli F, et al: Neuroimmunotherapy of advanced solid neoplasms with single evening subcutaneous injection of low-dose interleukin-2 and melatonin: preliminary results. Eur J Cancer 29: 185-189, 1993.
19. Jirillo A and Bonciarelli G: Treatment of advanced cancer with low dose radiotherapy, s.c. IL-2 and IFN-alpha. Proc ASCO: abs. 1364, 1993.
20. Schiller J, Morgan-Ihrig C and Levitt M: Concomitant administration of interleukin-2 plus tumor necrosis factor in advanced non-small cell lung cancer. Am J Clin Oncol 18: 47-51, 1995.
21. Tummarello D, Graziano F, Isidori P, et al: Consolidation biochemotherapy for patients with advanced non-small cell lung carcinoma responding to induction PVM (cisplatin, vinblastine, mitomycin-C) regimen. A phase II study. Cancer 77: 2251-2257, 1996.
22. Mantovani G, Macciò A, Mulas C, et al: Dose-intense phase II study of weekly cisplatin and epidoxorubicin plus medroxyprogesterone acetate and recombinant interleukin 2 in stage IIIB-IV non-small cell lung cancer. Oncol Rep 9: 661-670, 2002.
23. Ratto G, Zino P, Mirabelli S, et al: A randomized trial of adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 versus standard therapy in the postoperative treatment of resected nonsmall cell lung carcinoma. Cancer 78: 244-251, 1996. (Pubitemid 26234566)
24. Kimura H and Yamaguchi Y: Adjuvant immunotherapy with interleukin 2 and lymphokine-activated killer cells after non-curative resection of primary lung cancer. Lung Cancer 13: 31-44, 1995.
25. Ribas A, Butterfield L, Glaspy J and Economou J: Current developments in cancer vaccines and cellular immunotherapy. J Clin Oncol 21: 2415-2432, 2003. (Pubitemid 46621880)
26. Rosenberg S: Development of effective immunotherapy for the treatment of patients with cancer. J Am Coll Surg 198: 685-696, 2004.
27. Szabo S, Sullivan B, Peng S and Glimcher L: Molecular mechanisms regulating Th1 immune responses. Annu Rev Immunol 21: 713-758, 2003. (Pubitemid 37174546)
28. Banchereau J and Steinman R: Dendritic cells and the control of immunity. Nature 392: 245-252, 1998. (Pubitemid 28155090)
29. Whiteside T: Immune responses to malignancies. J Allergy Clin Immunol 125 (Suppl. 2): S272-S283, 2010.
30. Yoshino I, Yano T, Murata M, et al: Tumor-reactive T-cells accumulate in lung cancer tissues but fail to respond due to tumor cell-derived factor. Cancer Res 52: 775-781, 1992.
31. Papatestas A and Kark A: Peripheral lymphocyte counts in breast carcinoma. An index of immune competence. Cancer 34: 2014-2017, 1974.
32. Kim U, Papatestas A and Aufses AJ: Prognostic significance of peripheral lymphocyte counts and carcinoembryonic antigens in colorectal carcinoma. J Surg Oncol 8: 257-262, 1976.
33. Lavin P, Bruckner H and Plaxe S: Studies in prognostic factors relating to chemotherapy for advanced gastric cancer. Cancer 50: 2016-2023, 1982. (Pubitemid 13203600)
34. Maltoni M, Pirovano M, Nanni O, et al: Biological indices predictive of survival in 519 Italian terminally ill cancer patients. Italian Multicenter Study Group on Palliative Care. J Pain Symptom Manage 13: 1-9, 1997. (Pubitemid 27063350)
35. Riesco A: Five-year cancer cure: relation to total amount of peripheral lymphocytes and neutrophils. Cancer 25: 135-140, 1970.
36. Stanley K: Prognostic factors for survival in patients with inoperable lung cancer. J Natl Cancer Inst 65: 25-32, 1980.
37. Galon J, Costes A, Sanchez-Cabo F, et al: Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313: 1960-1964, 2006. (Pubitemid 44498003)
38. Galon J, Fridman W and Pagès F: The adaptive immunologic microenvironment in colorectal cancer: a novel perspective. Cancer Res 67: 1883-1886, 2007. (Pubitemid 46424201)
39. Lissoni P, Barni S, Ardizzoia A, et al: Prognostic factors of the clinical response to subcutaneous immunotherapy with interleukin-2 alone in patients with metastatic renal cell carcinoma. Oncology 51: 59-62, 1994. (Pubitemid 24008642)
40. Göhring B, Riemann D, Rebmann U, Heynemann H, Schabel J and Langner J: Prognostic value of the immunomonitoring of patients with renal cell carcinoma under therapy with IL-2/IFN-alpha-2 in combination with 5-FU. Urol Res 24: 297-303, 1996. (Pubitemid 26361769)
41. Blay J, Negrier S, Combaret V, Attali S, Goillot E, Merrouche Y, et al: Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res 52: 3317-3322, 1992.
42. Tartour E, Dorval T, Mosseri V, Deneux L, Mathiot C, Brailly H, et al: Serum interleukin 6 and C-reactive protein levels correlate with resistance to IL-2 therapy and poor survival in melanoma patients. Br J Cancer 69: 911-913, 1994. (Pubitemid 24140673)
43. Fumagalli L, Lissoni P, Di Felice G, et al: Pretreatment serum markers and lymphocyte response to interleukin-2 therapy. Br J Cancer May 80: 407-411, 1999.
44. Gérard C and Debruyne C: Immunotherapy in the landscape of new targeted treatments for non-small cell lung cancer. Mol Oncol 3: 409-424, 2009.
45. Pennell N and Lynch TJ: Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC. Oncologist 14: 399-411, 2009.
46. Ozao-Choy J, Ma G, Kao J, et al: The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res 69: 2514-2522, 2009.
47. Bradbury P and Shepherd F: Immunotherapy for lung cancer. J Thorac Oncol 3 (Suppl. 2): S164-S170, 2008. (Pubitemid 351786751)
48. Zitvogel L, Apetoh L, Ghiringhelli F and Kroemer G: Immunological aspects of cancer chemotherapy. Nat Rev Immunol 8: 59-73, 2008.
49. Neninger E, Verdecia B, Crombet T, et al: Combining an EGF-based cancer vaccine with chemotherapy in advanced non-small cell lung cancer. J Immunother 32: 92-99, 2009.
50. Curiel T: Regulatory T-cell development: is Foxp3 the decider? Nat Med 13: 250-253, 2007.
51. Curiel T: Tregs and rethinking cancer immunotherapy. J Clin Invest 117: 1167-1174, 2007.
52. + regulatory T cells in cancer patients. Blood 107: 2409-2414, 2006.
53. Vansteenkiste JF, Zielinski M, Dahabreh IJ, et al: Association of gene expression signature and clinical efficacy of MAGE-A3 antigen-specific cancer immunotherapeutic (ASCI) as adjuvant therapy in resected stage IB/II non-small cell lung cancer (NSCLC). Proc ASCO 26: abs. 7501, 2008.
54. Coate L and Shepherd F: Maintenance therapy in advanced non-small cell lung cancer. J Thorac Oncol 5: 723-734, 2010.
55. Kelly R, Gulley J and Giaccone G: Targeting the immune system in non-small-cell lung cancer: bridging the gap between promising concept and therapeutic reality. Clin Lung Cancer 11: 228-237, 2010.